Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Jackson

Showing results (131-140 of 182) with videos related to

Pageof 19
Sort By:
Journal of Asthma and Allergy|March 14, 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen SensitizationJonathan Corren, David J Jackson, Thomas B Casale, et al.
The Lancet. Respiratory Medicine|November 29, 2025
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trialDavid J Jackson, Njira L Lugogo, Mark Gurnell, et al.
Nature Medicine|May 2, 2017
Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbationMarie Toussaint, David J Jackson, Dawid Swieboda, et al.
Science Translational Medicine|October 3, 2014
Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammationJanine Beale, Annabelle Jayaraman, David J Jackson, et al.
Allergy|October 28, 2024
STING-dependent induction of neutrophilic asthma exacerbation in response to house dust miteYasmine Messaoud-Nacer, Elodie Culerier, Stéphanie Rose, et al.
The European Respiratory Journal|July 27, 2022
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE studyAndrew Menzies-Gow, Mark Gurnell, Liam G Heaney, et al.
Immunotherapy|February 11, 2025
Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publicationDavid J Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 11, 2024
Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With PolyangiitisAlexandra M Nanzer, Anne-Catherine Maynard-Paquette, Vardah Alam, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 2, 2025
Exploring the Long-Term Utility of Remotely Monitored FeNO Suppression Testing in Severe AsthmaJohn Busby, Joshua Holmes, Mohammed Almutairi, et al.
Plos One|September 1, 2017
Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthmaNadine Upton, David J Jackson, Alexandra A Nikonova, et al.
Pageof 19

Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
Journal of Asthma and Allergy|March 14, 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen SensitizationJonathan Corren, David J Jackson, Thomas B Casale, et al.
The Lancet. Respiratory Medicine|November 29, 2025
Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trialDavid J Jackson, Njira L Lugogo, Mark Gurnell, et al.
Nature Medicine|May 2, 2017
Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbationMarie Toussaint, David J Jackson, Dawid Swieboda, et al.
Science Translational Medicine|October 3, 2014
Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammationJanine Beale, Annabelle Jayaraman, David J Jackson, et al.
Allergy|October 28, 2024
STING-dependent induction of neutrophilic asthma exacerbation in response to house dust miteYasmine Messaoud-Nacer, Elodie Culerier, Stéphanie Rose, et al.
The European Respiratory Journal|July 27, 2022
Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE studyAndrew Menzies-Gow, Mark Gurnell, Liam G Heaney, et al.
Immunotherapy|February 11, 2025
Benralizumab in severe eosinophilic asthma by biologic use and key clinical subgroups: real-world XALOC-1 programme: a plain language summary of publicationDavid J Jackson, Girolamo Pelaia, Benjamin Emmanuel, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 11, 2024
Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With PolyangiitisAlexandra M Nanzer, Anne-Catherine Maynard-Paquette, Vardah Alam, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 2, 2025
Exploring the Long-Term Utility of Remotely Monitored FeNO Suppression Testing in Severe AsthmaJohn Busby, Joshua Holmes, Mohammed Almutairi, et al.
Plos One|September 1, 2017
Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthmaNadine Upton, David J Jackson, Alexandra A Nikonova, et al.
Pageof 19